Patients with chronic spontaneous urticaria demonstrated improved outcomes related to idiopathic angioedema after taking omalizumab, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
“The study was prompted by the observations that patients with idiopathic angioedema (IAE) tended to respond to omalizumab, but there were no prospective trials that we could point or refer to,” Vinay P. Goswamy, MD, an allergy and immunology fellow at University of Wisconsin School of Medicine and Public Health, told Healio.
“Additionally,